Multicenter Clinical Trial of a Phakic Implantable Collamer® Lens (ICL)

NCT ID: NCT04283149

Last Updated: 2025-03-07

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

327 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-30

Study Completion Date

2023-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This objective of this study is to evaluate the safety, and to collect supportive data on effectiveness of the EVO/EVO+ Visian® Implantable Collamer® Lens (ICL) in study participants who have a diagnosis of myopia or myopia with astigmatism. Primary study analysis will be evaluated when 300 primary eyes complete 6 months of follow-up. Final study analysis will be assessed when all treated eyes complete 36 months of follow-up.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will be conducted at up to 20 clinical sites in the United States by surgeons qualified by training and experience to implant STAAR ICLs.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myopia Myopic Astigmatism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

All enrolled eyes will undergo phakic eye surgery to have one of the available implantable collamer lenses EVO or EVO+ (spherical or toric) ICL implanted in their primary eye. Fellow eye surgery will occur between 7 and 14 days after primary eye surgery.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Primary Eyes

First implanted eyes of enrolled participants

Group Type EXPERIMENTAL

EVO/EVO+ Visian ICL

Intervention Type DEVICE

The investigational lenses are intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.

Fellow Eyes

Second implanted eyes of enrolled participants

Group Type EXPERIMENTAL

EVO/EVO+ Visian ICL

Intervention Type DEVICE

The investigational lenses are intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EVO/EVO+ Visian ICL

The investigational lenses are intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Moderate to high myopia or myopic astigmatism correctable with available EVO/EVO+ ICL powers.
* Stable refractive history within 0.50 D each cylinder and spherical equivalent (SE) for 1 year prior to implantation.
* Able and willing to return for scheduled follow-up examinations after surgery.
* Able to read, understand and provide written informed consent on the Institutional Review Board (IRB)-approved informed consent form (ICF) and provide authorization as appropriate for local privacy regulations.

Exclusion Criteria

* Insulin-dependent diabetes or diabetic retinopathy.
* History of previous ocular surgery.
* Cataract of any grade.
* Monocular.
* Pregnant or nursing women, or those who plan to become pregnant over the course of this clinical study.
Minimum Eligible Age

21 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Staar Surgical Company

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Joanne Egamino, PhD

Role: STUDY_DIRECTOR

VP, Global Clinical Affairs

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Barnett Dulaney Perkins

Phoenix, Arizona, United States

Site Status

Aloha Laser Vision, LLC

Honolulu, Hawaii, United States

Site Status

Price Vision Group,

Indianapolis, Indiana, United States

Site Status

Durrie Vision

Overland Park, Kansas, United States

Site Status

Solomon Eye Physicians and Surgeons/Bowie Vision Institute

Bowie, Maryland, United States

Site Status

Brinton Vision

St Louis, Missouri, United States

Site Status

Kugler Vision, PC

Omaha, Nebraska, United States

Site Status

Cleveland Eye Clinic

Brecksville, Ohio, United States

Site Status

Kremer Eye Center

King of Prussia, Pennsylvania, United States

Site Status

Vance Thompson Vision

Sioux Falls, South Dakota, United States

Site Status

Key-Whitman Eye Center

Dallas, Texas, United States

Site Status

Parkhurst NuVision

San Antonio, Texas, United States

Site Status

Hoopes Vision/Hoopes, Durrie, Rivera Research

Draper, Utah, United States

Site Status

The Eye Institute of Utah

Salt Lake City, Utah, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CP19-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Vault Evaluation After ICL Implantation
NCT06229119 COMPLETED PHASE4
ICL and LASIK for Hyperopic Astigmatism
NCT06742541 COMPLETED EARLY_PHASE1